India Drug Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The india drug delivery devices market size was valued at USD 6.88 billion in 2025 and estimated to grow from USD 7.62 billion in 2026 to reach USD 12.69 billion by 2031, at a CAGR of 10.74% during the forecast period (2026-2031). This report is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, Infusion Pumps, and More), Route of Administration (Injectable, Inhalational, Trandermal and More), and Application (Cancer, Cardiovascular Diseases, Diabetes and More), End User (Hospitals, Ambulatory Surgical Centers and More). The Market and Forecasts are Provided in Terms of Value (USD).

India Drug Delivery Devices Market Trends and Insights

Government Initiatives To Support Healthcare Access

Public spending on health rose to INR 89,287 crore in the 2024-25 Union Budget, channeling capital into primary care and device procurement within Tier 2 and Tier 3 cities. A streamlined approval pathway under the National Medical Devices Policy 2023 now accelerates clearances for injectable and implantable systems, cutting previous timelines by nearly one-third. Coupled with the Export Promotion Council for Medical Devices established in 2025, local firms gain faster export certifications and market entry support. These policy moves have widened adoption of affordable autoinjectors in semi-urban hospitals, fueling incremental demand across the India drug delivery devices market. Increased funding further supports clinical validation studies, ensuring new domestic products meet international standards.

High Demand for Cost-Effective Drugs Such as Biosimilars

Indian biosimilar producers, led by Biocon and Dr. Reddy’s, have launched low-cost versions of biologics that require dedicated delivery formats. Biocon’s generic liraglutide received clearance in 2024, triggering higher volumes of reusable pens designed for multi-dose regimens. As 15 additional peptide formulations near approval, demand has surged for compact autoinjectors configured for subcutaneous delivery in home settings. Urban adoption is especially strong, where clinicians now prescribe biosimilars to lower total treatment expenses, thereby expanding penetration of connected pens that upload dosing data to electronic medical records. The virtuous cycle between biosimilar growth and device innovation strengthens competitiveness of domestic firms in the India drug delivery devices market.

High Out-of-Pocket Spending Restricting Adoption of Advanced Implantable Systems

Out-of-pocket payments still make up 55% of India’s total health expenditure, limiting access to implantable pumps that cost USD 2,000-5,000 each. Reimbursement remains patchy outside large private insurers, pushing many patients toward lower-cost external pumps or conventional syringes. Uptake therefore concentrates in metro hospitals, creating uneven distribution across the India drug delivery devices market. Government plans to expand Pradhan Mantri Jan Arogya Yojana coverage to implantable drug platforms could ease this constraint, yet short-term adoption remains capped by affordability gaps in rural districts.

Other drivers and restraints analyzed in the detailed report include:

• High Burden of Chronic and Infectious Diseases Coupled with Aging Population
• Government and Market Players Initiatives for Boosting Domestic Manufacturing of Medical Devices
• Regulatory Uncertainty Around Classification of Combination Products Causing Approval Delays

Segment Analysis

Injectable delivery devices represented 44.30% of the India drug delivery devices market in 2025, reflecting high demand for pens, autoinjectors, and safety syringes across diabetes, oncology, and immunology care. Prefilled syringes minimize handling errors, while spring-loaded autoinjectors improve self-administration, particularly for aging patients who face dexterity challenges. Growing acceptance of biosimilars has expanded volume requirements for low-dead-space syringe formats and reusable pen platforms. Hospitals remain the largest customers, yet pharmacies increasingly dispense self-use devices, spurring retail distribution models.

Implantable devices are on track for a 11.62% CAGR to 2031. Materials such as titanium alloys and bioresorbable polymers provide controlled release for analgesics, antispasmodics, and neuroactive compounds. Deep-brain pumps demonstrate promise for Parkinson’s and epilepsy, with early clinical data showing sustained symptom control and lower systemic exposure. Domestic startups collaborate with IITs to refine miniaturized energy sources, aligning with Make-in-India objectives. As procurement costs fall, implantables will capture higher revenue share within the broader India drug delivery devices market size projections.

The injectable route held a 49.20% share of the India drug delivery devices market size in 2025, supported by biologicals that cannot be delivered orally. Smart pens store dosing logs, forwarding encrypted records to clinicians, and enable early detection of non-adherence. Cold-chain innovations, such as phase-change packaging, safeguard product integrity during last-mile delivery, widening geographic reach.

Nasal delivery is moving at an 11.12% CAGR through 2031. Mucoadhesive gels and surfactant-enhanced sprays improve drug absorption and can traverse the olfactory epithelium to reach the brain. Focus areas include migraine, Alzheimer’s, and even needle-free vaccine boosters. Indian firms license membrane-permeation enhancers, shortening development cycles. Pilot programs in tertiary hospitals show strong patient preference for nasal therapies, likely to boost future India drug delivery devices market share in central nervous system indications.

Complete Report Scope:

• By Device Type
  • Injectable Delivery Devices
  • Inhalation Delivery Devices
  • Infusion Pumps
  • Transdermal Patches
  • Implantable Drug Delivery Systems
  • Ocular Inserts and Delivery Implants
  • Nasal & Buccal Delivery Devices
• By Route of Administration
  • Injectable
  • Inhalation
  • Transdermal
  • Oral Mucosal (Buccal and Sublingual)
  • Ocular
  • Nasal
• By Application
  • Cancer
  • Cardiovascular Diseases
  • Diabetes
  • Respiratory and Infectious Diseases
  • Neurological Disorders
  • Others
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Home Healthcare Settings
  • Clinics and Others

List of Companies Covered in this Report:

• Sanofi
• Becton, Dickinson and Company (BD) India
• Cipla
• Novo Nordisk India Pvt Ltd
• Sun Pharmaceuticals Industries
• Biocon Ltd
• Dr. Reddy’s Laboratories Ltd
• Lupin
• Meril Life Sciences
• Zydus Lifesciences Ltd
• Medtronic
• Terumo India Pvt Ltd
• Baxter India Pvt Ltd
• B. Braun Medical (India) Pvt Ltd
• Ysomed
• Bayer
• Pfizer Ltd (India)
• Johnson & Johnson Pvt Ltd (Janssen)
• Roche Products (India) Pvt Ltd
• Abbott India Ltd

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support